î
îŒ
î
CorMedix Inc
CRMD12.190USD
+0.210+1.75%
çµå€Â 12/24, 13:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
955.08Mæ䟡ç·é¡
5.14çŽè¿12ã¶æPER
î
詳现æ å ± CorMedix Inc äŒæ¥å
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
CorMedix Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãCRMD
äŒç€ŸåCorMedix Inc
äžå Žæ¥Mar 25, 2010
æé«çµå¶è²¬ä»»è
ãCEOãTodisco (Joseph)
åŸæ¥å¡æ°64
蚌åžçš®é¡Ordinary Share
決ç®ææ«Mar 25
æ¬ç€Ÿæåšå°300 Connell Drive
éœåžBERKELEY HEIGHTS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·07922
é»è©±çªå·19085179500
ãŠã§ããµã€ãhttps://cormedix.com/
äŒæ¥ã³ãŒãCRMD
äžå Žæ¥Mar 25, 2010
æé«çµå¶è²¬ä»»è
ãCEOãTodisco (Joseph)
CorMedix Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
302.20K
--
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
87.65K
-31.34%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
69.69K
--
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
23.47K
--
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
13.33K
--
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
--
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Chief Operating Officer
Chief Operating Officer
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
302.20K
--
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
87.65K
-31.34%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
69.69K
--
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
23.47K
--
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
13.33K
--
åçå èš³
FY2025Q2
FY2025Q1
FY2024
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
39.74M
0.00%
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Mon, Nov 17
æŽæ°æå»: Mon, Nov 17
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
BlackRock Institutional Trust Company, N.A.
6.40%
Deep Track Capital LP
6.29%
Abdalkader (Shaibatalhamd Aymen)
5.90%
The Vanguard Group, Inc.
5.03%
Marshall Wace LLP
4.41%
ä»ã®
71.98%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
BlackRock Institutional Trust Company, N.A.
6.40%
Deep Track Capital LP
6.29%
Abdalkader (Shaibatalhamd Aymen)
5.90%
The Vanguard Group, Inc.
5.03%
Marshall Wace LLP
4.41%
ä»ã®
71.98%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
26.16%
Hedge Fund
16.79%
Investment Advisor/Hedge Fund
15.22%
Individual Investor
7.00%
Research Firm
2.04%
Pension Fund
1.09%
Bank and Trust
0.33%
Insurance Company
0.03%
Venture Capital
0.03%
ä»ã®
31.31%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Mon, Dec 8
æŽæ°æå»: Mon, Dec 8
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
338
43.86M
55.93%
+10.78K
2025Q3
340
43.85M
56.33%
+8.67M
2025Q2
304
34.76M
43.08%
+9.67M
2025Q1
267
24.95M
43.35%
-4.41M
2024Q4
241
23.99M
39.87%
+4.76M
2024Q3
216
19.17M
36.31%
+1.94M
2024Q2
207
17.23M
38.40%
-272.84K
2024Q1
207
17.37M
41.54%
-5.46M
2023Q4
207
18.82M
39.64%
+838.41K
2023Q3
199
17.96M
39.30%
-1.31M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
BlackRock Institutional Trust Company, N.A.
4.80M
6.42%
+485.88K
+11.27%
Jun 30, 2025
Abdalkader (Shaibatalhamd Aymen)
4.65M
6.22%
+4.65M
--
Aug 08, 2025
The Vanguard Group, Inc.
4.31M
5.77%
+675.49K
+18.59%
Jun 30, 2025
Marshall Wace LLP
2.58M
3.46%
+2.35M
+1019.17%
Jun 30, 2025
State Street Investment Management (US)
1.60M
2.15%
+62.52K
+4.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.60M
2.14%
+163.40K
+11.40%
Jun 30, 2025
Citadel Advisors LLC
1.71M
2.3%
+1.61M
+1517.64%
Jun 30, 2025
Alyeska Investment Group, L.P.
750.00K
1%
+750.00K
--
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
State Street SPDR S&P Pharmaceuticals ETF
2.01%
Invesco Biotechnology & Genome ETF
1.87%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.52%
VictoryShares Small Cap Free Cash Flow ETF
0.79%
First Trust Active Factor Small Cap ETF
0.3%
Janus Henderson Small Cap Growth Alpha ETF
0.25%
ALPS Barron's 400 ETF
0.21%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.19%
Vanguard US Multifactor ETF
0.16%
iShares Micro-Cap ETF
0.15%
詳现ãèŠã
State Street SPDR S&P Pharmaceuticals ETF
æ¯ç2.01%
Invesco Biotechnology & Genome ETF
æ¯ç1.87%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
æ¯ç1.52%
VictoryShares Small Cap Free Cash Flow ETF
æ¯ç0.79%
First Trust Active Factor Small Cap ETF
æ¯ç0.3%
Janus Henderson Small Cap Growth Alpha ETF
æ¯ç0.25%
ALPS Barron's 400 ETF
æ¯ç0.21%
Janus Henderson Small/Mid Cap Growth Alpha ETF
æ¯ç0.19%
Vanguard US Multifactor ETF
æ¯ç0.16%
iShares Micro-Cap ETF
æ¯ç0.15%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
CorMedix Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îCorMedix Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
BlackRock Institutional Trust Company, N.A.ã¯4.80Mæ ªãä¿æããŠãããããã¯å šäœã®6.42%ã«çžåœããŸãã
Abdalkader (Shaibatalhamd Aymen)ã¯4.65Mæ ªãä¿æããŠãããããã¯å šäœã®6.22%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯4.31Mæ ªãä¿æããŠãããããã¯å šäœã®5.77%ã«çžåœããŸãã
Marshall Wace LLPã¯2.58Mæ ªãä¿æããŠãããããã¯å šäœã®3.46%ã«çžåœããŸãã
State Street Investment Management (US)ã¯1.60Mæ ªãä¿æããŠãããããã¯å šäœã®2.15%ã«çžåœããŸãã
BlackRock Institutional Trust Company, N.A.ã¯4.80Mæ ªãä¿æããŠãããããã¯å šäœã®6.42%ã«çžåœããŸãã
Abdalkader (Shaibatalhamd Aymen)ã¯4.65Mæ ªãä¿æããŠãããããã¯å šäœã®6.22%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯4.31Mæ ªãä¿æããŠãããããã¯å šäœã®5.77%ã«çžåœããŸãã
Marshall Wace LLPã¯2.58Mæ ªãä¿æããŠãããããã¯å šäœã®3.46%ã«çžåœããŸãã
State Street Investment Management (US)ã¯1.60Mæ ªãä¿æããŠãããããã¯å šäœã®2.15%ã«çžåœããŸãã
CorMedix Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îCorMedix Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
BlackRock Institutional Trust Company, N.A.
Deep Track Capital LP
Abdalkader (Shaibatalhamd Aymen)
BlackRock Institutional Trust Company, N.A.
Deep Track Capital LP
Abdalkader (Shaibatalhamd Aymen)
CorMedix IncïŒCRMDïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q4æç¹ã§ãCorMedix Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯338瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ43.86Mã§ãå
šäœã®55.93%ãå ããŠããŸãã2025Q3ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-0.40%å¢å ããŠããŸãã
CorMedix Incã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2025Q2ã«ãããŠã--éšéãCorMedix Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
